

The Medicines Advice Service Evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence

Imogen Lyons,¹ Nicholas Barber,² David K Raynor,³ Li Wei⁴

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjqs-2015-004670>).

¹UCL Interaction Centre, University College London, London, UK

²Health Foundation, London, UK

³School of Healthcare, University of Leeds, Leeds, UK

⁴Research Department of Practice and Policy, UCL School of Pharmacy, University College London, London, UK

Correspondence to

Dr Imogen Lyons, UCL Interaction Centre, University College London, 66-72 Gower Street, London WC1E 6BT, UK; imogen.lyons.11@ucl.ac.uk

Received 4 August 2015

Revised 7 December 2015

Accepted 9 December 2015

Published Online First

11 January 2016



► <http://dx.doi.org/10.1136/bmjqs-2015-004400>

► <http://dx.doi.org/10.1136/bmjqs-2015-004886>



CrossMark

To cite: Lyons I, Barber N, Raynor DK, et al. *BMJ Qual Saf* 2016;**25**:759–769.

ABSTRACT

Aim To test the effectiveness of a tailored, pharmacist-led centralised advice service to improve adherence to patients on established medications.

Methods A parallel group randomised controlled trial was conducted. Patients prescribed at least one oral medication for type 2 diabetes and/or lipid regulation were eligible to participate. 677 patients of a mail-order pharmacy were recruited and randomised (340 intervention, 337 control). The intervention comprised two tailored telephone consultations with a pharmacist, 4–6 weeks apart, plus a written summary of the discussion and a medicines reminder chart. The primary outcome was self-reported adherence to medication at 6-month follow-up, collected via a postal questionnaire, analysed using generalised estimating equations. Secondary outcomes included prescription refill adherence, lipid and glycaemic control and patient satisfaction.

Results In intention-to-treat analysis 36/340 (10.6%) of the intervention group were non-adherent (<90% of medication taken in the past 7 days) at 6 months compared with 66/337 (19.6%) in the control group, yielding an unadjusted OR of 1.54 (95% CI 1.11 to 2.15, $p=0.01$). Analyses of dispensing data also showed that the odds of being classified as adherent ($\geq 90\%$) were 60% greater for the intervention group compared with the control group (OR 1.60, 95% CI 1.14 to 2.24, $p<0.01$). In a subsample of patients who provided blood samples, glycaemic and lipid control did not differ significantly between groups ($p=0.06$ and $p=0.24$, respectively) but positive trends were

observed. Ninety-two per cent of intervention group patients reported that they were satisfied with the service overall.

Conclusions A telephone intervention, led by a pharmacist and tailored to the individuals' needs, can significantly improve medication adherence in patients with long-term conditions, using a mail-order pharmacy. Further work is needed to confirm a trend towards improved clinical outcome.

Trial registration number NCT01864239.

BACKGROUND

Self-administered medicines play an important role in managing many long-term conditions but research suggests that as many as 30–50% of patients do not take their medicines as prescribed.^{1–3} Non-adherence may be unintentional, for example, forgetting to take medication, or it may be an intentional decision not to take medicines or to alter the way in which it is taken. Non-adherence can have costly outcomes for the individual patient, health systems and society as a whole, and is of particular and growing importance against the current backdrop of ageing populations, with rising prevalence of long-term conditions and associated increases in the prescription of medicines. In 2003, WHO suggested that innovations to improve treatment adherence may have a greater impact on public health than any further developments in specific medical treatments.² A recent estimate suggests that \$269 billion could be saved globally each year through

better adherence to medicines.⁴ However, although a vast literature has accumulated over several decades there remains a dearth of good quality conclusive evidence on how best to support medication adherence. A recent update of the Cochrane systematic review on adherence interventions found that just 5 out of 17 studies identified as having the lowest risk of bias successfully improved medication adherence and clinical outcomes; and no common characteristics associated with successful interventions were identified.⁵

Pharmacists increasingly provide a wide variety of interventions to support medication taking and there has been a growing body of research evaluating their role.⁶ A recent Cochrane systematic review on interventions to improve the safe and effective use of medicines identified interventions involving pharmacists in medicines management as having some evidence of positive impacts on adherence, medication problems and clinical outcomes but highlighted the need to strengthen the evidence base.⁷

In line with the approach advocated in the most recent update of the Cochrane systematic review of adherence interventions, the 'Medicines Advice Service' intervention in this study was adapted and refined from an intervention that had previously shown promise in a proof-of-concept randomised controlled trial (RCT), and which was subsequently developed from a centralised service into a nationally funded service in pharmacies in England, known as the New Medicine Service (NMS).⁸⁻⁹ A recently published large pragmatic RCT of the NMS reported that this pharmacist-led approach, focusing on individuals' problems and concerns with newly prescribed medicines, significantly improved the odds of self-reported adherence 10 weeks after initiating the new medicine.¹⁰ The NMS intervention was determined to be cost-effective based on economic modelling of the likely health impact of improved adherence in the long term.¹⁰ While new medicines are an important target for intervention, they represent a tiny proportion of overall prescriptions within long-term conditions. A recent study found that just 0.25% of prescription items are eligible for NMS.¹¹ Patients' experiences of problems, concerns and information needs are not restricted to new medicines, and research has found that adherence tends to drop off over time.¹²⁻¹³ The aim of this study was to examine the effectiveness of this relatively brief intervention in patients already established on long-term medications for diabetes and/or lipid regulation, who use mail order pharmacy services.

METHODS

Study design

The Medicines Advice Service Evaluation (MASE) was a single-site parallel group RCT of an intervention designed to improve medication adherence. Patients gave written informed consent prior to participation

by returning a signed consent form by post to the lead author. The study took place between December 2012 and September 2014.

Setting and participants

Patients prescribed at least one oral medication for type two diabetes and/or lipid regulation were recruited through 'Pharmacy2U', a UK National Health Service (NHS)-contracted internet and mail-order pharmacy which has over 300 000 registered patients and works with over 2000 general practitioner (GP) practices throughout England. Exclusion criteria included being under the age of 18 years, living outside of England, difficulty reading or understanding English or understanding the details of the study, prescribed drugs for dementia or showing signs of cognitive impairment, substantial hearing or sight impairment, having medications ordered by a caregiver/family member, or receiving a first prescription of a medication included in the study. Eligible patients, identified through electronic searches of the pharmacy's database, were posted an invitation letter and information booklet by the pharmacy.

Randomisation and concealment

Participants were randomly allocated, in blocks of four, to either the intervention or control group, using a 1:1 ratio. Block randomisation was used to help ensure a balanced workload for the intervention pharmacist as participants were recruited over time. A random number sequence was computer generated by LW, and IL used the sequence to assign participants to a group in the order in which baseline questionnaires were returned. Neither author had any role in the delivery of the intervention. Due to the nature of the intervention it was not feasible to blind participants or pharmacy staff to the patients' allocated group. To minimise potential reporting bias, the purpose of the study was presented as an opportunity to access advice from a pharmacist to address any issues associated with their medications, and did not refer to the concept of adherence.

Medicines advice service intervention

The Medicines Advice Service intervention is a pharmacist-led service, designed to be modifiable to support patients taking prescribed medication(s) for any long-term condition. In this study, the intervention was focused on lipid-lowering and antidiabetic medications. A report by the IMS Institute for Healthcare Informatics identified diabetes mellitus and hyperlipidaemia as having the highest avoidable costs within the US healthcare system.¹⁴ Both are significant risk factors for cardiovascular diseases, the most common cause of deaths from non-communicable disease worldwide, and are the leading contributors to the global disease burden in older people.¹⁵⁻¹⁶ Research suggests adherence to these

drugs is poor and they were therefore considered important to target in this intervention study.^{17 18}

The original intervention evaluated by Clifford *et al*⁸ and used in the NMS¹⁰ is described in the online appendix, along with the rationale for adaptations used in this study. The Medicines Advice Service intervention was comprised of three main components:

- ▶ Two telephone consultations with a pharmacist, 4–6 weeks apart
- ▶ A written summary of the discussion, posted to the patient after the first consultation
- ▶ A medicines reminder chart, posted to the patient after the first consultation.

The telephone consultations followed a semistructured condition-specific interview guide. Consultations aimed to identify any particular problems or concerns that the patient may be having. Although consultations were designed to specifically target issues related to medication adherence and the interview guide was designed to focus on the medicines used in the selection criteria, the emphasis could be tailored to individuals' specific needs, and a holistic approach was encouraged, taking into account any other prescribed or over-the-counter medications, or comorbid conditions. The pharmacist recorded any problems or concerns identified, and interventions provided, on a specially designed page on the pharmacy database. If the patient identified no particular issues, the pharmacist reinforced the importance of continuing to adhere to the prescribed medication regimen and offered healthy living advice (eg, dietary, weight loss, smoking cessation, etc). The follow-up phone call offered an opportunity to review any issues discussed in the initial consultation and to identify any new or outstanding problems to be addressed. At the end of the telephone consultation each participant was posted a letter summarising the key points discussed, and a personalised list of their current prescribed medications, known as a medicines reminder chart, indicating what each medicine is for, and how much of, and when, each should be taken.¹⁹

Standard care

Participants in the control group continued to receive their existing dispensing service, ordering prescribed

medications online or by telephone, and having prescriptions delivered to their address. Patients ordering by telephone speak to customer care staff, although there were no restrictions on their ability to contact the pharmacist if they wished to. The pharmacy does not provide automatic refills but does operate a refill reminder service where patients are contacted by pharmacy staff when their repeat prescription is due for renewal and they can arrange for the prescription to be approved by the doctor and dispensed. Participants who had previously signed up to this service continued to do so, regardless of their group allocation. Participants in both groups continued to be treated according to the clinical discretion of their GP, hospital specialists or other healthcare professional. No formal arrangements were made to contact other healthcare providers about the trial.

Prior to the start of recruitment, pharmacy staff (including the pharmacist who delivered the intervention, and customer care staff who scheduled the intervention appointments) received training on the background and rationale for the study, the implementation of the study protocol, and the intervention and control group procedures. One fully qualified pharmacist, who had completed postgraduate training in independent and supplementary prescribing, delivered the intervention. All intervention calls were audio recorded and a small random selection (n=6) was reviewed and discussed within the research team early in the intervention phase. The intervention pharmacist subsequently received feedback from the research team and had an opportunity to discuss any challenges encountered. Regular contact was maintained with pharmacy staff throughout to provide ongoing support and to resolve any emerging issues.

Outcome measures and data collection

Self-complete postal questionnaires were used to collect data at baseline, and 4 weeks and 6 months after the follow-up telephone consultation (figure 1). Questionnaires were sent with a freepost return envelope, and a reminder letter was sent if the questionnaire was unreturned after 2–3 weeks. Biomedical data was collected at baseline and 6 month follow-up. Additional data extracted from pharmacy records included age, gender, number of items on repeat




Figure 1 Intervention and data collection timeline.

prescription, use of repeat prescription reminder service and medications dispensed. The primary outcome was self-reported adherence to lipid-lowering and/or oral diabetes medication(s), measured using questions from the Diagnostic Adherence to Medication Scale (DAMS).²⁰ This short scale was developed following a systematic review of self-report adherence measures to address some of the gaps in existing measures.²¹ Content, face and preliminary construct validity has been established in a sample of 100 primary care patients taking a range of medicines for various conditions. Adherence ratings on the DAMS have been found to correlate with previously validated self-report measures.²⁰ This instrument records the amount of each medication prescribed, and participants were asked to report how much of each they missed in the previous 7 days, to allow calculation of an adherence rate, either for one medicine individually or overall. The DAMS also includes a question to determine if any non-adherence reported is intentional, unintentional or both. Questions about taking too much medication were not included in this study. In the absence of a gold standard measure of adherence, a multimethod approach, including a self-report and another more objective measure, has been recommended.² Therefore, we also included a measure of refill adherence. A medication possession ratio (MPR) was calculated from electronic pharmacy dispensing data. For each antidiabetes and lipid-lowering drug, the sum of the days' supply was calculated from an index date to a final follow-up point (31 August 2014), and divided by the number of days within that range. For the control group, the index date was the first dispensing date after consent was received. For the intervention group, it was the date the first refill was dispensed after the first intervention phone call. Any day's supply dispensed for any period beyond the final follow-up was discounted when calculating the MPR. If a participant stopped or changed a medication it was censored from the last refill date. Maximum adherence was capped at 100%, even if a patient was dispensed more of a drug than they had been instructed to take.

Participants were also asked to provide an optional blood sample at baseline and 6 month follow-up, using a self-administered finger prick test. Samples were posted to a central accredited laboratory where they were analysed. HbA1c was measured by a high-performance liquid chromatography using a cation exchange column. Total cholesterol was measured using enzymatic colorimetric methods.

On a 4 week follow-up self-report questionnaire, participants in the intervention group were asked to rate their agreement with the statement "Overall, I was satisfied with the Medicines Advice Service" on a 7-point Likert scale (1=very strongly agree, 7=very strongly disagree).

Data on the length of consultation calls was accessed from audio recordings. A random sample of

10% of pharmacy consultation records (n=31) was also accessed and analysed descriptively to explore the content of the intervention and possible mechanisms of action.

Sample size and statistical analysis

Based on a similar pharmacy intervention study, a sample size calculation was carried out estimating a reduction in the proportion of patients who self-report non-adherence from 15% to 7.5%.⁸ With 80% power and a two-sided significance level of 0.05, the required sample size was determined to be 278 participants in each group. Assuming a 10% dropout, we aimed to recruit approximately 612 individuals.

Adherence data is typically highly positively skewed and therefore the self-report and refill adherence data were dichotomised using a threshold of 90%. This cut point was chosen as it is inclusive in detecting non-adherence and has also been found to be significantly associated with health outcomes.^{23 24}

The primary analysis was performed according to the intention-to-treat (ITT) principle to minimise potential bias from missing responses. Multiple imputations, using the fully conditional specification method, was used and 20 complete imputed data sets were created. The imputation model included the primary outcome (self-reported non-adherence at 4 weeks and 6 months post intervention), which was missing for 15.5% and 19.2% of the sample, respectively. Other variables included had no more than 4% missing data. The online appendix provides further details on the handling of missing values. Generalised estimating equation (GEE) analyses were performed. There were no differences in adjusted GEE analyses (adjusted for age, gender, therapeutic group, number of prescription items, reminder service, baseline adherence), therefore only unadjusted analyses are presented here.

In secondary analyses, χ^2 tests were also used to compare the proportion of adherent and non-adherent individuals between the intervention and control groups at single time points (4 weeks and 6 months). Logistic regression was used to determine the odds of adherence in each group compared with the other. Participants were also categorised according to whether or not they met guideline recommended targets for cholesterol and HbA1c levels, and χ^2 tests were used to detect any significant differences between groups. All analyses were carried out using SPSS V.21,²⁵ and all statistical tests were two-sided adopting a 0.05 significance level.

RESULTS

Participants

A total of 785 patients (17.8%) agreed to participate in the study by returning a signed consent form. At baseline, 684 patients were eligible and returned a completed questionnaire. Seven were excluded or withdrew prior to randomisation, leaving 340 in the

intervention group and 337 in the control group. The flow of participants through the study is outlined in figure 2. Table 1 presents the baseline characteristics of the 677 participants who were randomised. The intervention and control groups were similar in terms of all sociodemographic, clinical and medication-related variables measured at baseline.

Delivery of the intervention

Ninety-two per cent of the intervention group (n=310) completed the intervention. Eighteen people (5%) did not receive either telephone consultation, and a further 12 received the first telephone consultation but did not complete the follow-up consultation.

The most common reasons for non-completion were not answering multiple calls and/or responding to messages to arrange an appointment, and not answering at the time of the appointment. Several attempts were made to contact participants and to reschedule missed appointments. Initial consultation calls lasted a median of 16 min 40 s (IQR 13–22 min). The median length of the follow-up consultations was 5 min 36 s (IQR 3–8 min). The median length of time between consultations was 35 days (IQR 28–41 days).

Content of the intervention

Of 31 randomly selected cases for which pharmacy records were accessed, 26 were consultations for




Figure 2 Flow of participants through the study.

Table 1 Baseline characteristics of participants

Participant characteristics	Intervention n=340	Control n=337
Age in years (mean, SD)	69.9 (9.2)	69.9 (10.1)
Gender (female)	133 (39.1)	148 (43.9)
Marital status ¹		
Single, never married	22 (6.5)	24 (7.2)
Married/civil partnership/living with partner	228 (67.1)	210 (62.7)
Widowed	54 (15.9)	64 (19.1)
Separated or divorced	36 (10.6)	37 (11.0)
Living alone ¹	92 (27.1)	98 (29.3)
Education ²		
Primary school or no formal education	53 (16.0)	51 (15.8)
Lower secondary level (eg, GCSE/O level or equivalent)	57 (17.2)	73 (22.6)
Upper secondary level (eg, A-levels/Highers or equivalent)	32 (9.7)	35 (10.8)
Other qualifications below degree level (eg, vocational qualifications)	91 (27.5)	87 (26.9)
Degree or higher degree	98 (29.6)	77 (23.8)
English as first language ³	328 (96.8)	328 (97.9)
Ethnicity (White) ⁴	324 (95.9)	325 (97.3)
Employment status ⁴		
Employed/self-employed	60 (17.8)	69 (20.7)
Retired	267 (79.0)	246 (73.7)
Full-time home maker/carer/unemployed/disabled or too ill to work	11 (3.3)	19 (5.7)
Self-reported general health ⁵		
Excellent	27 (8.0)	31 (9.3)
Very good	82 (24.3)	91 (27.3)
Good	131 (38.9)	123 (36.9)
Fair	79 (23.4)	69 (20.7)
Poor	18 (5.3)	19 (5.7)
Therapeutic group		
Hyperlipidaemia	261 (76.8)	253 (75.1)
Type 2 diabetes	14 (4.1)	18 (5.3)
Hyperlipidaemia and type 2 diabetes	65 (19.1)	66 (19.6)
Prescription reminder service		
Telephone reminder	155 (45.6)	175 (51.9)
Email reminder ⁶	101 (29.7)	90 (26.7)
No reminder	84 (24.7)	72 (21.4)
Exemption from prescription payment ³	329 (97.1)	315 (94.0)
Total number of items on repeat prescription list (median, IQR)	6.00 (5)	6.00 (5)
Total number of cholesterol and/or diabetes medications prescribed		
1	258 (75.9)	260 (77.2)
2	51 (15.0)	52 (15.4)
3	20 (5.9)	17 (5.0)
4	9 (2.6)	7 (2.1)
5	2 (0.6)	1 (0.3)
Self-reported adherence to lipid-lowering and/or diabetes medication in the previous 7 days (Diagnostic Adherence to Medication Scale) ⁷		
Median (IQR)	100 (0)	100 (0)
<90% adherence	44 (13.3)	43 (13.1)
Patients meeting guideline targets		
Total cholesterol <5 mmol/L ⁸	86 (56.2)	82 (62.6)
Glycated haemoglobin (HbA1c) <7% ⁹	23 (44.2)	20 (44.4)

¹Missing=2, ² missing=23, ³ missing=3, ⁴ missing=5, ⁵ missing=7, ⁶ includes one postal reminder, ⁷ missing=16, ⁸ n=284, ⁹ n=97. Data are number (%) unless otherwise stated.

cholesterol medicines only, 1 was for a consultation related to diabetes medication only, and 4 consultations related to cholesterol and diabetes medicines. In two-thirds of the first consultation calls sampled, the pharmacist recorded no problems, concerns or information needs. For the remaining 10 participants, 23 issues were recorded. The most common problem recorded was a potential side effect ($n=7$, 22.6%), followed by a need for more information about medicines ($n=4$, 13.3%). Table 2 illustrates some examples of the types of issues and outcomes recorded by the pharmacist during consultations.

Effect of the intervention on self-reported non-adherence

Four weeks and 6 months after intervention the intervention group had significantly better self-reported adherence (defined as $\geq 90\%$ of medication taken in the previous 7 days) compared with the control group, across all analyses (table 3). According to the primary ITT GEE analysis, the intervention group had 54% increased odds of being adherent compared with the control group (OR 1.54, 95% CI 1.11 to 2.15, $p=0.010$). Complete case and available case analyses produced less conservative estimates. The results of adjusted and unadjusted logistic regression analyses at 4 week follow-up and 6-month follow-up are presented in table 3.

Effect of the intervention on pharmacy refill adherence

Analyses of dispensing data drawn from pharmacy records showed that over a longer follow-up period,

averaging 434 days, 88/294 (29.9%) of the intervention group were categorised as non-adherent ($<90\%$ of medication available) compared with 127/313 (40.6%) of the control group, yielding an OR of 1.60 in favour of the intervention group (95% CI 1.14 to 2.24, $p=0.006$).

Effect of the intervention on glycaemic and lipid control

Valid results were obtained from 169 cholesterol tests and 41 HbA1c tests at follow-up. Six months after intervention, the intervention group had twice the proportion of participants achieving HbA1c less than 7% (66.7%, $n=16$) compared with the control group (31.3%, $n=5$), with this difference approaching statistical significance ($p=0.061$). The proportion of patients meeting guideline targets for total cholesterol levels (<5 mmol/L) was also higher in the intervention group (65.3%, $n=64$) compared with the control group (55.1%, $n=38$) at follow-up, although the differences were not statistically significant ($p=0.24$).

Satisfaction with the Medicines Advice Service

On the whole satisfaction with the Medicines Advice Service was high, with 91.8% ($n=245$) agreeing that they were satisfied overall. Just four participants (1.5%) expressed any dissatisfaction with the service. Two did not give a reason for dissatisfaction. One participant stated that the service was not really useful as he had no concerns about his medicines and one other participant described a problem with the pharmacy's services in general rather than with the

Table 2 Examples of issues and outcomes extracted from a random sample of pharmacist records of telephone consultations

ID	Issues reported by the patient during first telephone consultation	Advice pharmacist recorded as given during the first telephone consultation	Outcome reported to pharmacist at follow-up consultation
541	Has not been taking atorvastatin for 2–3 months. Thought they were causing insomnia (took at night), and didn't think they were doing anything. Also was put off by media reports about statins in the papers. Decided that he did not want to carry on with them	Advised him to take the atorvastatin in the morning. Gave more info about the recent statin media stories and that the evidence still shows they have more benefits than risks in most patients	Has been taking them daily since the first call, and without side effects. He is happy with this, and is due soon to receive the results of his latest cholesterol test
374	Says that he misses all of his tablets (except warfarin) for a day, around once a month, intentionally (if he gets a headache, etc) as a kind of 'detox'	Advised that this was not necessary	He has taken the tablets without stopping since the first call
111	Had side effects with simvastatin; changed to atorvastatin; side effects not as bad, but still takes infrequently. Only takes one tablet once a week (instead of once daily)	Advised to try taking it in the morning instead of at night to see if this minimises side effects. See general practitioner (GP) if side effects persist—briefly discussed alternative options for example, ezetimibe, fibrates	Has taken a dose in the morning, every single morning since our last call. Slight leg pain but can 'walk this off' and is very happy with the atorvastatin tablets now and intends to continue with it each day
777	No issues with his simvastatin. But found the aspirin tablets were hard to remove from packaging sometimes	Put note on system for us to send these in bottles in future	Finds this much easier than using the blister packs
630	He is taking simvastatin 40 mg and also amlodipine (and experiences muscle aches and pains)	Asked him to ask GP if the statin should come down to 20 mg as per recent Medicines and Healthcare products Regulatory Agency guidance	Found this helpful but has not made the appointment with his GP yet to discuss this
872	Does not have annual check-ups for cholesterol/liver function tests	Advised to mention to GP or diabetic nurse when next at the surgery	Has not had the opportunity to do this yet but reinforced the advice

Table 3 Unadjusted and adjusted effect of the intervention on self-reported non-adherence measured using the Diagnostic Adherence to Medication Scale at 4 week follow-up and 6 month follow-up

	χ^2	Proportion <90% adherent			Logistic Regression			Generalised estimating equations analysis		
		n	Intervention	Control	p value	Unadjusted	Adjusted*	Unadjusted	n	OR (95% CI, p value)
Four-week follow-up										
Intention to treat (ITT)	677	39/340 (11.5)	68/337 (20.2)	†		677	1.93 (1.22 to 3.05, 0.005)	677	2.20 (1.33 to 3.65, 0.002)	
Available cases†	564	19/270 (7.0)	50/294 (17.0)	0.000		564	2.71 (1.55 to 4.72, 0.000)	556	3.53 (1.87 to 6.67, 0.000)	
Complete cases§	494	17/244 (7.0)	39/250 (15.6)	0.004		494	2.47 (1.35 to 4.50, 0.003)	494	3.43 (1.72 to 6.84, 0.000)	
6 month follow-up										
ITT	677	36/340 (10.6)	66/337 (19.6)	†		677	2.04 (1.23 to 3.40, 0.006)	677	2.24 (1.29 to 3.88, 0.004)	1.54 (1.11 to 2.15, 0.010)
Available cases	541	16/270 (5.9)	41/271 (15.1)	0.001		541	2.83 (1.55 to 5.18, 0.001)	532	3.40 (1.75 to 6.61, 0.000)	1.82 (1.26 to 2.61, 0.001)
Complete cases	494	14/244 (5.7)	35/250 (14.0)	0.003		494	2.67 (1.40 to 5.11, 0.003)	494	3.48 (1.69 to 7.15, 0.001)	1.69 (1.10 to 2.61, 0.017)

*Logistic regression adjusted for age, gender, therapeutic group, number of prescription items, reminder service, baseline adherence

†No p values are provided for ITT analyses. SPSS does not support doing a χ^2 test on imputed data sets.

‡Available case analysis included all available data at each time point.

§Complete case analysis included only those who had questionnaire data available at all three data collection points.

Medicines Advice Service in particular. Regression analyses identified no significant predictors of overall satisfaction. The majority of participants (81.6%, n=217) agreed that they would recommend the service to someone else in their position.

DISCUSSION

The MASE RCT has shown that mail-order pharmacy patients who participated in a tailored intervention delivered by a pharmacist had significantly increased odds of adherence, measured using self-report and pharmacy refill data, compared with a usual care control group. The findings were robust, producing consistent effects in ITT and complete case analyses.

The magnitude of the effect on self-reported adherence in our study is consistent with similar community pharmacy-based interventions in a variety of long-term conditions in the UK.^{8 10 26} The study also provides insight into the effect of pharmacist intervention on medication refill adherence. Studies using dispensing data are relatively common in the USA but this is one of the first UK studies to examine adherence based on pharmacy prescription refill rates. This approach allows for objective assessment of the effect of the intervention over a considerably longer period of time, compared with previous studies.^{8 10} The findings indicate that this relatively brief intervention can have a sustained impact on adherence. However, the proportion of patients classified as non-adherent according to dispensing data was higher than indicated in self-report data. It may be that the discrepancy reflects real differences in adherence in the time periods each measure covers (7 days compared with mean 434 days). Alternatively, social desirability bias in self-report may have resulted in an overestimation of the true level of adherence, and/or refill adherence may be underestimated for the one-fifth of patients in this study who reported using another pharmacy at least once to collect their diabetes or cholesterol drugs.

Glycaemic and lipid control were also assessed as objective markers of clinical impact, and non-significant improvements in the proportion of patients meeting guideline targets were observed in the intervention group compared with the control group. However, the study used a novel method of collecting blood samples at a distance and many patients reported difficulty drawing a sufficient sample of blood using the finger prick testing kit supplied. The number of samples available for analysis at follow-up was therefore small and further appropriately powered research is required to determine whether these findings are reliable and clinically meaningful. Most, though not all, reviews have identified improvements in cholesterol and glycaemic levels associated with pharmacist intervention.^{27–30}

High rates of intervention completion indicated that the service was also acceptable to patients. Data

collected on patients' satisfaction and willingness to recommend the service support this view. These findings are largely consistent with other studies looking at patients' perspectives on pharmacist intervention.^{31 32}

Strengths and limitations

This large randomised controlled trial, incorporating data from multiple sources (patient self report, pharmacy records, blood results) and exploring outcomes over considerably longer follow-up periods, strengthens and extends previous findings on the efficacy of tailored pharmacist intervention in improving adherence to long-term medications. However, there are a number of limitations. First, although the required sample size was exceeded in this trial, a large number of eligible patients were invited to take part, and the positive response rate was just over 17%. In order to explore the possibility of recruitment bias, the MASE study sample was compared with anonymised data supplied by the pharmacy on four variables: age, gender, number of items on repeat prescription and uptake of the pharmacy's repeat prescription reminder service. No major differences were found in the characteristics of those who agreed to take part compared with the overall eligible population on these variables.

Although the intervention was developed using the available evidence and theory, and key elements had been tested in previous research, these were applied in a novel setting, and additional new components and methods of data collection may well have benefitted from a feasibility and piloting stage, as recommended in the Medical Research Council guidelines on developing and evaluating complex interventions.³³ This may have helped to identify methods to improve the initial response rate and the return of viable blood samples.

Participants were recruited from a single mail-order pharmacy and it is possible the results may not be generalisable to other settings. Recent database studies from the USA have suggested that use of mail-order pharmacy is associated with better refill adherence and health outcomes when compared with regular brick and mortar pharmacies.^{34 35} Patients in the UK are free to obtain their NHS prescriptions from any pharmacy. No published research has explored the characteristics of patients who opt to use mail-order pharmacy. A comparison of our baseline demographic and clinical data with other UK studies suggests that patients who use mail-order pharmacy in the UK may not differ significantly from those using regular community pharmacy services.^{8 10 36–38}

A third limitation linked to generalisability, was the delivery of the intervention by just one pharmacist, who holds a postgraduate qualification in independent and supplementary prescribing, and may have been particularly motivated and enabled to consistently and

rigorously deliver the intervention. Further testing of the intervention with a wider group of pharmacists would be beneficial. However, the widespread implementation of similar services such as the NMS and Medicines Use Reviews in community pharmacies, suggests that this type of intervention is transferable to different settings and pharmacists.

Implications for practice and future research

To the best of our knowledge this is the first UK study to explore the impact of pharmacist intervention in a cohort of patients using mail-order pharmacy. Internet and mail-order pharmacy is a relatively new phenomenon in the UK and represents a small but growing proportion of pharmacies.³⁹ The results of this trial demonstrate that it is feasible and effective to provide adherence support to mail-order pharmacy users, using a combination of telephone consultations and written information. Further research is needed to establish cost-effectiveness in the mail-order setting. Previous work with similar interventions suggests that this is a cost-effective approach, with improvements in adherence translating into modest healthcare gains and cost savings in the long term.^{9 10} Although the mail-order context has some unique characteristics, parallels between this intervention and existing services such as NMS suggest that this approach could be feasibly implemented within community pharmacy settings, or that these services could be extended and adapted to better facilitate mail-order pharmacies. Indeed, evidence from the evaluation of the NMS, along with findings from the PharmOutcomes database indicates that even in a community pharmacy setting telephone consultations are considered convenient and appropriate, with the majority of NMS interventions delivered by telephone.^{10 40 41}

CONCLUSION

The results presented here have shown that tailored intervention, delivered by a pharmacist, comprising spoken information and advice by phone and written information by post, was acceptable to patients, and was effective in significantly improving medication adherence in a mail-order pharmacy cohort. These results are robust, using two methods of measuring adherence, and the effect is still present more than 6 months after the intervention. The findings provide further support for the enhanced role of pharmacists in supporting and advising patients with their medicines to improve outcomes.

Acknowledgements The authors would like to thank all the staff at Pharmacy2U who helped to facilitate this research. In particular we would like to thank Dr Julian Harrison, for his collaboration and contribution to the conception and design of the study, and the development of the intervention, and Mr Phil Day, who helped develop the intervention content and delivered the intervention. We are also grateful to Gill Dorer, a patient representative, who provided feedback on the study protocol and materials. Finally, we would like to gratefully

acknowledge all the individuals who gave their time to participate in this research.

Contributors NB, DKR and IL designed the study. IL carried out the data analyses, with input from LW, and drafted the manuscript. All authors contributed to editing and revising of the manuscript, and approved the final manuscript.

Funding This work was jointly funded by the UCL School of Pharmacy and Pharmacy2U as part of an initiative from the UCL School of Pharmacy which half funds PhD students with industry providing the other half. Pharmacy2U had no role in the analysis or interpretation of the data, or in the preparation or review of the manuscript.

Competing interests DKR is co-founder and academic advisor to Luto Research which develops, refines and tests health information materials. All other authors declare that they have no competing interests.

Ethics approval The London Brent Research Ethics Committee (12/LO/1657) and the NHS Leeds R&D Office (L001_22_11_12_0000).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data collection questionnaires are available on request from the corresponding author.

REFERENCES

- Vermeire E, Hearnshaw H, Royen PV, *et al.* Patient adherence to treatment: three decades of research. a comprehensive review. *J Clin Pharm Ther* 2001;26:331–42.
- WHO. *Adherence to long-term therapies: evidence for Action*. Geneva: World Health Organisation, 2003.
- Horne R, Weinman J, Barber N, *et al.* *Concordance, adherence and compliance in medicine taking*: National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO), 2005.
- IMS Institute for Healthcare Informatics. Advancing the responsible use of medicines: Applying levers for change. 2012. <http://www.responsibleuseofmedicines.org/wp-content/uploads/2012/09/IIHI-Ministers-Report-170912-Final.pdf> (accessed 8 Oct 2012).
- Nieuwlaat R, Wilczynski N, Navarro T, *et al.* Interventions for enhancing medication adherence. *Cochrane Database Syst Rev* 2014;11:CD000011.
- Andersson M, Garfield S, Eliasson L, *et al.* Delivery of patient adherence support: a systematic review of the role of pharmacists and doctors. *Patient Intell* 2014;6:31–42.
- Ryan R, Santesso N, Lowe D, *et al.* Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev* 2014;4:CD007768.
- Clifford S, Barber N, Elliott R, *et al.* Patient-centred advice is effective in improving adherence to medicines. *Pharm World Sci* 2006;28:165–70.
- Elliott RA, Barber N, Clifford S, *et al.* The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. *Pharm World Sci* 2008;30:17–23.
- Elliott RA, Boyd MJ, Waring J, *et al.* *Department of Health Policy Research Programme Project 'Understanding and Appraising the New Medicines Service in the NHS in England'—A randomised controlled trial and economic evaluation with qualitative appraisal comparing the effectiveness and cost effectiveness of the New Medicines Service in community pharmacies in England*. University of Nottingham, 2014.
- Wells KM, Boyd MJ, Thornley T, *et al.* What proportion of prescription items dispensed in community pharmacies are eligible for the New Medicine Service? *BMC Health Serv Res* 2014;14:115.
- Twigg MJ, Poland F, Bhattacharya D, *et al.* The current and future roles of community pharmacists: Views and experiences of patients with type 2 diabetes. *Res Social Adm Pharm* 2013;9:777–89.
- Benner JS, Glynn RJ, Mogun H, *et al.* Long-term persistence in use of statin therapy in elderly patients. *JAMA* 2002;288:455–61.
- IMS Institute for Healthcare Informatics. Avoidable costs in US healthcare: The \$200 billion opportunity from using medicines more responsibly. 2013. <http://www.imshealth.com/portal/site/imshealth/menuitem.18c196991f79283fddc0ddc01ad8c22a/?vgnnextoid=0711e590cb4dc310VgnVCM100000a48d2ca2RCRD&vgnnextfmt=default> (accessed 20 Jun 2013).
- Prince MJ, Wu F, Guo Y, *et al.* The burden of disease in older people and implications for health policy and practice. *Lancet* 2015;385:549–62.
- WHO. *Global status report on noncommunicable diseases 2014*. Geneva: World Health Organisation, 2014.
- Cramer JA. A systematic review of adherence with medications for diabetes. *Diabetes Care* 2004;27:1218–24.
- Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. *Cochrane Database Syst Rev* 2010;(3):CD004371. <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004371/frame.html> (accessed 27 Jan 2012).
- Raynor DK. Medicine reminder charts—a key tool for delivering the new medicine service. *Pharm J* 2011;287:393–4.
- Garfield S, Eliasson L, Clifford S, *et al.* Developing the Diagnostic Adherence to Medication Scale (the DAMS) for use in clinical practice. *BMC Health Serv Res* 2012;12:350.
- Garfield S, Clifford S, Eliasson L, *et al.* Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. *BMC Med Res Methodol* 2011;11:149.
- Morisky DE, Ang A, Krousel-Wood M, *et al.* Predictive validity of a medication adherence measure in an outpatient setting. *J Clin Hypertens* 2008;10:348–54.
- Bouchard M-H, Dragomir A, Blais L, *et al.* Impact of adherence to statins on coronary artery disease in primary prevention. *Br J Clin Pharmacol* 2007;63:698–708.
- Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. *Curr Med Res Opin* 2013;29:175–80.
- IBM. SPSS Statistics for Windows [program]. 21.0 version. Armonk, NY: IBM Corp, 2012.
- Blenkinsopp A, Phelan M, Bourne J, *et al.* Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. *Int J Pharm Pract* 2000;8:165–75.
- Machado M, Nassor N, Bajcar JM, *et al.* Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. *Ann Pharmacother* 2008;42:1195–207.
- Santschi V, Chiolerio A, Paradis G, *et al.* Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Care* 2012;35:2706–17.

- 29 Lindenmeyer A, Hearnshaw H, Vermeire E, *et al.* Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. *J Clin Pharm Ther* 2006;31:409–19.
- 30 Aguiar PM, Brito GdC, Correr CJ, *et al.* Exploring the quality of systematic reviews on pharmacist interventions in patients with diabetes: an overview. *Ann Pharmacother* 2014;48:887–96.
- 31 Tinelli M, Blenkinsopp A, Bond C. Development, validation and application of a patient satisfaction scale for a community pharmacy medicines-management service. *Int J Pharm Pract* 2011;19:144–55.
- 32 Carter SR, Chen TF, White L. Home medicines reviews: a quantitative study of the views of recipients and eligible non-recipients. *Int J Pharm Pract* 2012;20:209–17.
- 33 Craig P, Dieppe P, Macintyre S, *et al.* Developing and evaluating complex interventions: the new medical research council guidance. *BMJ* 2008;337:a1655.
- 34 Iyengar R, Henderson R, Visaria J, *et al.* Dispensing channel and medication adherence: evidence across 3 therapy classes. *Am J Manag Care* 2013;19:798–804.
- 35 Schmittiel JA, Karter AJ, Dyer W, *et al.* The comparative effectiveness of mail order pharmacy use vs. local pharmacy use on LDL-C control in new statin users. *J Gen Intern Med* 2011;26:1396–402.
- 36 Kotseva K, Wood D, De Backer G, *et al.* EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. *Eur J Cardiovasc Prev Rehabil* 2010;17:530–40.
- 37 Morse A. *The management of adult diabetes services in the NHS. Report by the Comptroller and Auditor General.* London: National Audit Office, 2012.
- 38 The Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. *Fam Pract* 2007;24:189–200.
- 39 HSCIC. *General Pharmaceutical Services in England: 2003–04 to 2012–13.* London: Health and Social Care Information Centre, 2013.
- 40 PSNC. Evaluation of Evidence Provided by PharmOutcomes New Medicine Service Data. Secondary Evaluation of Evidence Provided by PharmOutcomes New Medicine Service Data. 2012. <http://psnc.org.uk/services-commissioning/advanced-services/nms/service-evaluation-nms-statistics-and-pharmoutcomes-data/>.
- 41 Lucas B, Blenkinsopp A. Community pharmacists' experience and perceptions of the New Medicines Service (NMS). *Int J Pharm Pract* 2015.

Appendix

1. Further information about the intervention, its development and rationale

The vast discordant research literature in the field of non-adherence provides limited assistance to guide intervention design. Reviewers frequently conclude that there is insufficient information available to specify effective strategies and to guide decisions about the precise nature of interventions.¹ Nieuwlaat and colleagues, for example, reported that they could identify no common characteristics associated with successful interventions.² In the absence of solid evidence about what approaches are most effective, we elected to adapt and refine an existing intervention that had previously shown promise in a large UK based RCT. This research demonstrated that pharmacists can successfully support the optimal use of newly prescribed medicines for long-term conditions in a cost-effective manner through telephone consultation.^{3,4} Although, this original proof-of-concept research was limited to a four-week follow-up of self-reported adherence, the patient-centred, tailored intervention had a sound theoretical foundation and as a central telephone-based service was suitable for delivery in a mail order pharmacy context. At the time of the conception of this study, the intervention had recently been adopted as a national NHS-funded New Medicine Service (NMS), provided by community pharmacist in both face-to-face and telephone consultations. In the current study we sought to further develop this intervention and explore its application to other patients already established on long-term medicines, in the context of a mail order pharmacy. The original NMS intervention and its adapted form, named the Medicines Advice Service, are described here.

The New Medicine Service Intervention

The theoretical base of the NMS intervention and the proof of concept research underpinning it is Leventhal's Self Regulatory Model (SRM), incorporating the Necessity-Concerns Framework (NCF).^{5,6} This approach recognises that adherence to medication is influenced by each individual's beliefs about their condition and treatment, as well as their experience of it. Alongside theory, empirical evidence suggests that patients' attitudes and beliefs are the factors most closely associated with non-adherence, and reviews have identified individually tailored patient-centred approaches as the most efficacious at improving medication adherence.^{7,8}

The NMS intervention is designed to first elicit each patient's experiences with, and concerns about, their new medicine, allowing the pharmacist to tailor the information and advice provided to the individual's specific needs, taking account of their personal beliefs and preferences. The NMS intervention is constructed of three stages:

1. Patient engagement – patient is identified by, or referred to, a community pharmacist and invited to take part in the service when receiving a prescription for a relevant new medicine (NMS is currently targeted at four disease groups: asthma/COPD, hypertension, type 2 diabetes, antiplatelets/anticoagulants).
2. Intervention – 7-14 days later the patient engages in either a face-to-face or telephone consultation with the pharmacist.
3. Follow up – 14-21 days later the patient has a follow up consultation with the pharmacist.

The intervention consultation and follow up are guided by an interview schedule. The pharmacist, having identified any concerns or issues the patient has with their medicine, can then make efforts to resolve these issues, referring the patient back to their GP where necessary. Further information about the NMS can be found in the service specification at <http://psnc.org.uk/services-commissioning/advanced-services/nms/>.

Adaptation and development - the Medicines Advice Service Intervention

For this study, the original intervention was adapted to be delivered in a new context, targeting different patient groups. The design of the new intervention, which was named the Medicines Advice Service, was influenced by the practical experiences of the research and pharmacy team, guided by theoretical understanding, empirical evidence, and the available resources.

One of the key differences from the NMS intervention was its targeting toward patients already established on medications in the long term, rather than those beginning a new medicine. Although research indicates that the largest decline in persistence occurs within the first 6 months of treatment, there is evidence of subsequent continued steady drop-off in adherence over time. Benner et al.⁹ found that adherence to statins was 79 per cent after 3 months, 56 per cent after 6 months, 56 per cent after 12 months, 35 per cent after 60 months, with just about one in four patients still considered adherent at 5 years. This suggests that people may experience problems with their medication that persist well beyond the beginning of a

new therapy, or encounter new problems over time. The Royal Pharmaceutical Society of Great Britain's recently published good practice guidance on medicines optimisation recognises that "the patient's experience may change over time even if the medicines do not."^{10, p. 6} Like the NMS, our intervention targeted all patients regardless of their current adherence status.

One pharmacist delivered all the Medicines Advice Service intervention consultations via telephone. The intervention in the original proof of concept study was similarly delivered as a centralised telephone service by a small number of pharmacists from one organisation. However, the intervention has been successfully scaled up, and the NMS can be provided by any accredited community pharmacist, either face-to-face or by telephone, and has been found to produce a similar effect size.

In keeping with the structure of the NMS intervention, our intervention comprised two tailored consultations with a pharmacist, guided by a semi-structured interview schedule. Consultations aimed to identify any particular problems or concerns that the patient may be having and began with an open question "How are you getting on with your cholesterol/diabetes medicines?" The interview guide included questions related to the management of the condition as well as medications to encourage a more holistic approach. Additionally, participants received follow-up written information, comprising a summary of the information and advice imparted over the telephone, and a personalised medicines reminder chart which lists the individual's medicines, what they are for, the times they are to be taken and any other relevant instructions. There is strong evidence to support the provision of combined verbal and written communication. Research indicates that between 40 and 80 per cent of medical information provided by healthcare professionals is forgotten immediately.¹¹ Moreover, almost half of what people recall is in fact incorrect.¹²⁻¹³ Although there is more limited evidence available on the utility of medicines charts, some studies suggest that they are effective in improving knowledge and adherence, and qualitative research had identified a desire among patients for an up-to-date medication list of what to take, as well as when and how.¹⁴⁻¹⁶ Charts were automatically generated within the pharmacy database but could be amended by the pharmacist based on their consultations with the patient to ensure that it was accurate and relevant to the patient's current dosing regimen. The provision of a written summary and a medicines reminder chart was intended to improve both the efficacy and sustainability of the intervention by providing an additional re-iteration and reference of the key points from telephone consultations and clarification of the patient's medication regimen.


References

1. Viswanathan M, Golin CE, Jones CD, et al. Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States A Systematic Review. *Ann Intern Med* 2012;**157**(11):785-95.
2. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews* 2014, 2014.
3. Clifford S, Barber N, Elliott R, et al. Patient-centred advice is effective in improving adherence to medicines. *Pharm World Sci* 2006;**28**(3):165-70.
4. Elliott RA, Barber N, Clifford S, et al. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. *Pharm World Sci* 2008;**30**(1):17-23.
5. Leventhal H, Cameron L. Behavioral theories and the problem of compliance. *Patient Educ Couns* 1987;**10**:117-38.
6. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res* 1999;**47**(6):555-67.
7. Kardas P, Morrison V, Fargher E, et al. Report on the Determinants of Patient Non-Adherence with Short-Term Therapies and Treatments for Chronic Diseases in Europe. In: ABC PROJECT TEAM, ed. *Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use of medicines in Europe - Final Report of the ABC Project*. Lodz, 2012.
8. van Eijken M, Tsang S, Wensing M, et al. Interventions to improve medication compliance in older patients living in the community - A systematic review of the literature. *Drugs Aging* 2003;**20**(3):229-40.
9. Benner JS, Glynn RJ, Mogun H, et al. Long-term Persistence in Use of Statin Therapy in Elderly Patients. *JAMA: The Journal of the American Medical Association* 2002;**288**(4):455-61.
10. Picton C, Wright H. *Medicines Optimisation: Helping patients to make the most of medicines - Good practice guidance for healthcare professionals in England*. London: Royal Pharmaceutical Society, 2013.
11. Kessels RPC. Patients' memory for medical information. *J R Soc Med* 2003;**96**:219-22.
12. Morgan M, Horne R. Explaining patients' behaviour. In: Horne R, Weinman J, Barber N, et al., eds. *Concordance, adherence and compliance in medicine taking*. Brighton: National Coordinating Centre for NHS Service Delivery and Organisation R & D., 2005.
13. DiMatteo MR, Haskard-Zolnieriek KB, Martin LR. Improving patient adherence: a three-factor model to guide practice. *Health Psychology Review* 2012;**6**(1):74-91.
14. Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated reminder charts on patients' compliance with drug regimens. *Br Med J* 1993;**306**:1158-61.
15. Gabriel M, Gagnon JP, Bryan CK. Improved Patient Compliance through Use of a Daily Drug Reminder Chart *Am J Public Health* 1977;**67**(10):968-69.
16. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: Benefits and barriers. *Research in Social and Administrative Pharmacy* 2012;**8**(1):4-16.

2. Missing data and multiple imputation

The most common reasons for missing data in this study were: participants not returning a questionnaire, participants not fully or correctly completing the questionnaire, participant withdrawal, or participants who became ineligible during the study. Multiple imputation, using the fully conditional specification method in SPSS, was used to impute missing data. Linear regression was used for continuous variables and logistic regression for categorical variables. The imputation model included the primary outcome (self-reported non-adherence at four weeks and six months post-intervention), which was missing for 15.5% and 19.2% of the sample, respectively. Other variables included in the imputation model had no more than 4% missing data (marital status, living arrangements, education, employment, ethnicity, English language, self-reported general health, number of GP visits in three months prior to study, beliefs about medicines, and medication-related problems, concerns and information needs). The variables: group allocation, age, gender, therapeutic group, use of refill reminder service, and number of items on repeat prescription were extracted from the pharmacy database and had no missing values. For outcomes comprising multiple separate questionnaire items, such as the BMQ, each questionnaire item was imputed and the overall outcome score calculated from the imputed data. Twenty complete imputed data sets were created, as recommended in more recent literature (Sterne et al., 2009), which were analysed separately and the results then combined.

3. Study Protocol



Research Protocol

The Medicines Advice Service Evaluation

-

A randomised controlled trial of a pharmacy-based
telephone intervention to support patients taking medication
for a long-term condition

UCL School of Pharmacy & Pharmacy2U

Imogen Lyons
PhD Student
UCL School of Pharmacy

CONTENTS

1. Summary	4
2. Background	4
3. Aims and Objectives.....	5
4. Study Design	5
5. Setting and Participants	5
5.1 Selection Criteria.....	6
5.1.1 Inclusion Criteria	6
5.1.2 Exclusion Criteria	6
5.2 Recruitment	6
6. Intervention	7
6.1 Intervention Group – Medicines Advice Service	7
6.1.1 Telephone Call and Summary Letter	7
6.1.2 Follow-up Telephone Call	8
6.2 Control Group	9
7. Study Procedures	9
7.1 Randomisation	9
7.2 Intervention procedure.....	9
7.3 Quality Assurance and Maintaining Intervention Fidelity.....	10
7.4 Training	10
8. Data Collection and Outcome Measures	11
8.1 Data Collection.....	11
8.1.1 Postal Questionnaire.....	11
8.1.2 Qualitative Interviews.....	11
8.2 Outcome Measures.....	11
8.2.1 Self-reported Adherence	12

8.2.2 Pharmacy Refill Records.....	15
8.2.3 Clinical Indicators of Health	15
8.2.4 Healthcare Utilisation	15
8.2.5 Beliefs about Medicines	16
8.2.6 Medicine-related Problems	16
8.2.7 Demographics and General Health	16
8.2.8 Patients' Satisfaction with the Intervention	16
8.3 Process Measures	17
9. Statistical Considerations.....	17
9.1 Sample Size	17
9.2 Statistical Analysis.....	17
References	18
Appendix.....	21
Data Collection and Intervention Time Frame.....	21

1. SUMMARY

Non-adherence to medication is common and although some interventions have shown promise in improving adherence, the findings are inconsistent. This study aims to examine the impact of a pharmacy-based telephone intervention on medication adherence and health outcomes in patients taking medicines for a long-term condition.

Patients will be identified from a database of pharmacy patients. We hope to recruit approximately 600 patients to take part in the study. Half of these will be randomised to receive the intervention, while the other half will continue to receive their usual care from the pharmacy. The intervention will consist of telephone support provided by a pharmacist together with follow-up written information. Participants in the study will be followed up over six months. Data will be collected from both groups prior to the intervention and at two points during and after the study to determine any changes as a result of the intervention. The main outcome of interest is adherence to medication. Other outcomes that we will explore include clinical indicators of health and healthcare service use. The results of this study will be used to guide future intervention development and implementation.

2. BACKGROUND

The World Health Organization (2003) proposed that innovations to improve treatment adherence may have a greater impact on population health than any further developments in specific medical treatments. However, thus far there is a limited evidence base for interventions to increase adherence to medication. Several systematic reviews have been carried out and reported that the literature in this field is of poor quality and the findings are inconclusive as to how best to intervene (Haynes et al., 2008, Van Wijk et al., 2005). The UK Department of Health (2008) also highlighted the need for more robust evidence to strengthen the commissioning of services to support adherence to medicines. This study attempts to address this gap by developing and rigorously evaluating a new adherence intervention based on existing research and theory.

The causes of non-adherence are complex and what evidence exists to date, suggests that multi-faceted, tailored interventions are more effective in improving adherence than single and generalised interventions (Haynes et al., 2008, van Eijken et al., 2003). The 2009 NICE guidelines on medication adherence state that no specific intervention can be recommended for all patients and that any intervention must be tailored to the specific circumstances of the individual patient (Nunes et al., 2009).

Pharmacists have been identified as well-placed and well qualified to deliver tailored adherence interventions (Cutrona et al., 2010). An RCT carried out by Clifford et al (2006) found that a patient-centred telephone intervention, delivered by a community pharmacist and focussing on individuals'

problems and concerns about medicines, resulted in improvements in adherence and cost savings in the use of healthcare costs. However, this study had a follow up of just four weeks and although there is growing evidence that telephone interventions can be effective in improving self-care activities and health outcomes the evidence is inconsistent and requires further study (Walker et al., 2011). It is therefore hoped that this study will provide further insight into the efficacy of a pharmacy-based telephone intervention to improve medication adherence and health outcomes.

3. AIMS AND OBJECTIVES

The overall aim of the study is to evaluate the impact of a pharmacy-based telephone intervention to support patients taking medications for a long-term condition.

Key objectives are to:

- Develop a patient-centred tailored intervention
- Conduct a randomized controlled trial to test the effectiveness of the intervention compared to usual care on the following outcomes:
 - Adherence to medication
 - Clinical health outcomes
 - Medicine-related problems and concerns
 - Beliefs about medicines
 - Health services utilization
- Evaluate the process of intervention implementation and identify factors that may impact on replicability and generalisability.

4. STUDY DESIGN

The study will use a single-site, randomized controlled parallel groups trial with one intervention arm and one control arm to assess the effectiveness of a pharmacy-based telephone intervention compared to usual care in improving adherence to medication and improving health outcomes.

Recruitment will take place over a 6-month period and each participant will be followed up for 6 months. The total duration of participant involvement in the trial is therefore likely to be 12 months from the first randomisation.

5. SETTING AND PARTICIPANTS

The intervention will target patients taking medication for two common long-term conditions: type 2 Diabetes and Hyperlipidemia. Participants will be recruited through Pharmacy2U, an established UK internet and mail-order pharmacy.

5.1 SELECTION CRITERIA

Potential participants will be identified through electronic searches of the active NHS patient cohort contained within the pharmacy's computer database, according to the predefined eligibility criteria below.

5.1.1 INCLUSION CRITERIA

- All NHS patients prescribed medication(s) for at least one of the following conditions:
 - Type 2 Diabetes
 - Hyperlipidemia

5.1.2 EXCLUSION CRITERIA

- Patients living outside of England
- Patients with no access to a telephone
- Patients under the age of 18
- Patients unable to give written informed consent
- Patients on drugs for dementia
- Patients showing signs of dementia or cognitive impairment in conversation
- Patients with substantial hearing or sight impairment
- Patients whose medications are ordered by a caregiver/family member
- Patients with insufficient English to take part in the telephone intervention
- Patients living with someone already taking part in the study
- Patients newly prescribed a medication for the conditions listed in the inclusion criteria

5.2 RECRUITMENT

The number of participants recruited at any given time will be limited by the availability of the intervention pharmacist. Recruitment therefore will be staggered over a period of at least six months. At each recruitment point a random sample of patients who meet the inclusion criteria will be invited to participate in the study. A small pilot study will be undertaken to identify the proportion of selected patients who are likely to consent to take part in the study. These findings will be used to estimate the number of patients who will need to be invited to participate in order to achieve the sample size required. The size of the invitation communication may be adjusted as further experience and understanding of the response rate is developed.

Each potential participant will receive an invitation letter with a patient information sheet, consent form and prepaid return envelope. Patients who do not return a consent form within 2 to 3 weeks may be contacted by telephone by a member of the Pharmacy2U customer care team and again invited to participate if they wish and have the opportunity to have any questions answered. The same process will be repeated at each subsequent round of recruitment, with all those previously invited to take part excluded from the search.

6. INTERVENTION

The intervention being studied is a patient-centred telephone service to support patients taking prescribed medicines for a long-term condition. The intervention will include three communications: two telephone consultations and written information by post. The intervention is intended to target medication adherence but the specific emphasis will be tailored to the individual participant's specific medication and condition-related needs.

6.1 INTERVENTION GROUP – MEDICINES ADVICE SERVICE

Participants in the intervention arm will receive a scheduled telephone consultation with a pharmacist, a written summary of the consultation and a medicines reminder chart. A second follow-up telephone call completes the intervention.

The intervention will be delivered by fully qualified pharmacists. Wherever possible the same pharmacist will conduct all the sessions for a given participant. During each interaction with the patient the pharmacist will focus on developing rapport with the patient, establishing a collaborative relationship and encouraging open communication. Pharmacists will aim to be non-judgemental and encouraging, in a supportive rather than a directive manner.

All patients will continue to be treated according to the clinical discretion of their GP, hospital specialists or any other healthcare providers throughout the trial.

6.1.1 TELEPHONE CALL AND SUMMARY LETTER

The first intervention telephone call will take place within 3-4 weeks of enrolling in the study. At the beginning of the first intervention telephone call the pharmacist will check the participant meets the selection criteria, briefly reiterate the overall structure of the intervention, and will confirm that the participant is happy to continue.

The initial consultation will follow a semi-structured condition-specific interview guide designed to establish the patient's adherence to medicines, identify any problems the patient may be having and assess the patient's needs for further information or advice. The interview schedule has been

adapted from one successfully used in previous research studies (Clifford et al 2006) and currently being used as part of the recently established New Medicine Service. The pharmacist will also have access to the patient's pharmacy record and will be able to see a complete list of the patient's medications and dispensing history.

Based on the information elicited the pharmacist can confirm and prioritise the issues identified with the patient and together explore potential solutions. The pharmacist can tailor advice to each patient's individual needs. The intervention will take a holistic approach, focussing not only on the medicines used in the selection criteria but also taking into account any other prescribed or over-the-counter medications, or co-morbid conditions.

The components used in the intervention will address both intentional and unintentional non-adherence and may include:

- Information or suggestions to help address any concerns about taking medication
- Information or suggestions to help address any existing problems with medicines
- Tips and tactics to avoid common side effects
- Advice about how to deal with side effects.
- Information about strategies to help patients remember to take their medications as prescribed e.g. alarms, multi-compartment compliance aids, phone/tablet apps, etc
- Signposting to educational videos and websites – e.g. video of accurate inhaler technique.
- Discussion about potential formulation or dosing schedule changes
- Referral to prescriber where necessary

At the end of the interaction the pharmacist will summarise the outcomes of the discussion and actions to be taken, and will schedule a follow-up telephone call. The pharmacist will record any issues identified and interventions provided using a specially designed intervention page on the pharmacy database. The outcomes of the intervention will be documented and a summary will be posted to the patient. All participants will also receive a personalised printed medicine reminder chart, which will be discussed with them during the intervention phone call.

6.1.2 FOLLOW-UP TELEPHONE CALL

Four to six weeks after the first telephone call, the patient will receive a follow-up phone call from the pharmacist as scheduled. The follow-up intervention will follow a similar process and will focus on assessing medication adherence, reviewing progress, addressing any new problems or concerns, and providing healthy lifestyle advice.

6.2 CONTROL GROUP

Participants in the control group will continue to receive their existing dispensing service from Pharmacy2U. This includes ordering their prescribed medications online or through a dedicated telephone service and having their prescriptions delivered to their home or office by recorded delivery. Customers ordering by telephone usually speak to a member of the customer care team. It is therefore unlikely that the intervention pharmacist(s) will have contact with control group participants.

Participants in the control group who have previously opted to avail of Pharmacy2U's prescription reminder service, either via telephone or email, will continue to do so throughout the study period. Patients who use this service are contacted by a member of the customer care team when their prescription is due for renewal and if requested Pharmacy2U arrange for the prescription to be approved by their doctor and dispensed on their behalf.

7. STUDY PROCEDURES

7.1 RANDOMISATION

Randomisation will be at the level of the individual participant and will take place after the participant has completed the baseline data collection. Participants will be randomly allocated in equal numbers to either the intervention or control group. If necessary, minimisation will be used to ensure groups are balanced on factors such as use of the pharmacy refill reminder service. According to the Consort guidelines (Moher et al., 2010) minimisation is considered an acceptable alternative and methodological equivalent to random assignment to ensure that a balance is maintained between groups for several patient factors identified prior to the beginning of the study. Using minimisation, the first patient is randomly assigned to a group; all subsequent patients are allocated to the group which will ensure the groups remain as closely balanced as possible on the characteristics selected.

The researcher will contact the pharmacy to inform them that consent has been received and the allocated group for each consented participant. Each participant will also receive a letter from the researcher informing them of their allocation. Due to the nature of the intervention it will not be possible to blind participants or pharmacy staff to the patient's allocated group.

7.2 INTERVENTION PROCEDURE

Participants who have been randomized to the intervention group will receive either a call or an email from the Pharmacy2U customer care team to arrange an appointment with the pharmacist.

Emails will provide a link to available time slots for the participant to book as convenient. Participants who schedule an appointment using this system will receive email confirmation of the appointment time and date. Customers who do not have an email address registered with Pharmacy2U or do not respond to the initial appointment scheduling email will receive a call from the customer care team to schedule an appointment.

In most cases the pharmacist will arrange the follow-up intervention appointment with the participant at the end of the first intervention telephone consultation. Where this is not possible, the customer care team will schedule the next appointment using a similar process.

7.3 QUALITY ASSURANCE AND MAINTAINING INTERVENTION FIDELITY

Limiting the study to one site allows greater control over the intervention. There will be a small number of pharmacists involved in the study, which will reduce the impact of variation in individual practices. However, a detailed intervention manual will be developed to help ensure adherence of the intervention pharmacist(s) to the study protocol. The intervention manual will be developed in consultation with the intervention pharmacists to ensure it is relevant and user-friendly, and will be updated as the study progresses and more experience is gained.

The pharmacist will be responsible for tailoring the intervention to the specific needs of each individual. The intervention pharmacists will carefully document the participants' responses and each component of the intervention applied for each patient, using a specially designed intervention page on the pharmacy database. All intervention telephone calls will be recorded and a random selection will be reviewed to monitor quality and give feedback to the intervention pharmacist(s). The researchers will maintain regular contact with the pharmacy staff to resolve any emerging issues.

7.4 TRAINING

The intervention will be delivered by fully qualified pharmacists, who will have received training in the implementation of the study protocol and specific procedures. This training will be supported by a written manual. Customer care staff who will be involved in the recruitment and scheduling of intervention appointments will also receive training in the background and rationale for the study, and in the implementation of the study protocol and the intervention and control procedures.

8. DATA COLLECTION AND OUTCOME MEASURES

8.1 DATA COLLECTION

Both quantitative and qualitative data will be collected. Data will be collected via self-complete postal questionnaire at three time points: baseline, four weeks and six months.

A qualitative telephone interview will be conducted with a subsample of participants in the intervention group approximately 4 months into the study. Further data may be extracted from pharmacy records and the NHS hospital episodes statistics secondary usage data. Further information on the data collected at each time point can be found in the Appendix.

8.1.1 POSTAL QUESTIONNAIRE

The postal questionnaire at baseline will include demographic questions, a measure of general health, a section on medication beliefs, problems and adherence, and questions on healthcare utilisation. A second questionnaire posted to participants at four weeks will include questions on medication beliefs, problems and adherence, and healthcare utilisation. Participants in the intervention group will receive a supplementary questionnaire assessing their satisfaction with the telephone service. A similar questionnaire will be posted to participants 6 months post intervention.

8.1.2 QUALITATIVE INTERVIEWS

Qualitative interviews will be conducted with a purposive sample of approximately 30 participants in the intervention group. Interviews will explore participants' experiences of the study and will examine their perceptions of and satisfaction with the telephone service.

The aims and objectives of the qualitative component of the study are to:

- Provide in-depth information about how the intervention works from the perspective of participants
- Identify and understand outcomes of the intervention from the perspective of the participants
- Collect information to explain the success or failure of the intervention, such as the mode of communication, structure and components of the intervention.
- Identify areas needing improvement in future implementation of the intervention

8.2 OUTCOME MEASURES

The primary outcome of interest in this study is self-reported adherence to medication. Secondary outcome measures will include: pharmacy refill adherence, clinical health outcomes, healthcare resource use, beliefs about medicines, and medicine-related problems and concerns.

8.2.1 SELF-REPORTED ADHERENCE

The primary outcome measure in this study is self-reported medication adherence. A range of methods are available to measure medication adherence, including: electronic monitoring of medication containers to record each opening, pill counts, pharmacological or biochemical markers in blood or urine, dispensing records, patient diaries and self-report. All these methods are indicative rather than absolute measures of adherence, each with its own advantages and disadvantages. Previous research indicates that in the absence of a 'gold standard' measure, researchers must choose the most appropriate measure in the specific context (Garfield et al., 2011).

Self-report measures have long been the most widely used method of assessing adherence in both research and practice settings (Williams et al., 2012). Patient-report methods are relatively inexpensive, simple and convenient to use (Osterberg and Blaschke, 2005, Bosworth et al., 2006). Self-reported adherence rates tend to be higher than those obtained from more objective measures such as electronic monitoring data, however, recent reviews and meta-analysis have reported moderate correlations between self-report, electronic monitoring, pill counts and pharmacy refill data, indicating that self-reports are still a valid measure (Garfield et al., 2011, Shi et al., 2010). Self-reported adherence measures have also been found to have good predictive validity with clinical outcomes, such as viral load in HIV and blood pressure (Garfield et al., 2011, Williams et al., 2012). Furthermore, self-report measures can be qualitatively informative, providing an opportunity to help understand and interpret adherence behaviours (Kyngas et al., 2000, Bosworth et al., 2006, Williams et al., 2012).

Many self-report instruments have been developed to assess both generic and disease-specific medication adherence, a number of which have been explored for use in this study (Bosworth et al., 2006). A recent systematic review carried out by Garfield et al (2011) identified 58 different self-report measures, with limited evidence available to help decide which types of scales are most acceptable, reliable and obtain the most accurate information. Among the most commonly used self-report adherence measures are the 4-item or 8-item Morisky Medication Adherence Scale (Morisky et al., 1986, Morisky et al., 2008) and the Brief Medication Questionnaire (Svarstad et al., 1999). The evidence for validity and reliability for these existing scales remains inconclusive and each scale has limitations. For example, Garfield et al. (2011) reported that approximately half the papers reporting reliability data for the Morisky scale found low internal reliability, while the other half reported acceptable reliability. The Morisky instrument has been found to be a poor predictor of low adherence or clinical outcome (Farmer, 1999, Dunbar-Jacob et al., 2012). Moreover, this scale measures adherence as a categorical variable and does not allow for the quantification of individual

patient's adherence or adherence for different drugs within a regimen (Doró et al., 2011). Finally, the Morisky Scales are not time specific and are therefore impractical for measuring changes in adherence over time. None of the questions on the 4-item scale and six of the eight items in the Morisky-8 ask about general adherence rather than specifying a time period.

The Brief Medication Questionnaire (BMQ), developed by Svarstad et al (1999) to screen for adherence and perceived barriers to adherence, requires participants to list all the medications they have taken in the previous week, with detailed information about doses times and number of pills taken and missed. It also collects information about what the medicine is being taken for, whether the patient thinks it is working, whether medicines bother the patient, and about common problems with medicines. It is a long, complex and cumbersome instrument, and does not address medicines which the patients may have been prescribed but has not taken in the previous week. Furthermore, although it was found to have good sensitivity for predicting non-adherence of more than 20% of prescribed medicine, it has very low sensitivity for identifying sporadic non-adherence (defined as taking 1-19% more or less medicine than prescribed).

In the absence of a suitable standardised questionnaire, a measure was sought that could meet the following criteria:

- Generic rather than disease-specific and therefore suitable to use for multiple conditions
- Suitable for patients taking a single medication or multiple medications for one or more conditions.
- Brief and acceptable, not overly time consuming or intrusive
- Sensitive to change over time
- Provides continuous outcome data

The measure selected consists of three questions; two about the amount of medication taken and one about the reasons medication was missed. The first question asks people to estimate their adherence using a visual analogue scale (VAS). The VAS requires participants to mark a point along a scale indicating their best guess about how much of the medicines they have taken within the previous month. The VAS is a quick, simple measure and has shown promising evidence of validity in recent studies (Giordano et al., 2004, Oyugi et al., 2004, Pearson et al., 2007). Moderate to high correlations have been reported between the VAS and other self-report measures, unannounced pill counts and prescription refill data, as well as with HIV viral load suppression (Nau et al., 2007, Kalichman et al., 2009).

Several recent studies report that general estimates of adherence over longer periods produce similar or more accurate rates than more specific measures of missed doses (Walsh et al., 2002, Giordano et al., 2004, Simoni et al., 2006, Lu et al., 2008, Doró et al., 2011). The VAS question

asks about adherence over a one-month period. Williams et al (2012) state that for general estimates of adherence, a one-month period is a reasonable time frame for most patient groups. One advantage of using a one-month time period is that it is more likely than shorter time frames to be reflective of general patterns of adherence over time, and therefore more likely to be linked with clinical outcomes.

Although estimation recall measures such as the VAS appear promising, they lack more detailed information about patterns of adherence and may be more susceptible to recall bias (Garfield et al., 2011). The second question, drawn from the Diagnostic Adherence to Medication Scale (DAMS), therefore, requires participants to recall how many doses of each of their cholesterol and/or diabetes drugs they have missed taking in the previous 7 days (Garfield et al., 2012). A review comparing self-report and objective adherence measures in HIV found that the most common self-report item was an open-ended question about the number of doses missed over a defined period of time (Simoni et al., 2006). When asking participants to provide more specific details shorter time periods are more appropriate (Williams et al., 2012). Adherence rates reflecting a shorter time period are generally thought to be less likely to be affected by recall bias. Some researchers have reported that the accuracy of adherence reports decline after just 24 hours (Wagner and Miller, 2004). However, others have contradicted this finding moderately strong correlations between 1, 2, 3, 4, 5, 6 and 7-day measures, and reporting no difference in adherence recall between 1 and 3 days, when compared to MEMS data (Pearson et al., 2007, Jerant et al., 2008). A 7-day recall period was chosen as it always incorporates a weekend, when adherence behaviours have been found to differ. Haynes et al. (2002) assert that missing one or more pills in a week is an indication of a problem with low adherence.

Research suggests that patients sometimes have difficulty remembering the names of their medications and their prescribed dosing regimen (Catz et al., 2000, Gagné and Godin, 2005). Williams et al. (2012) recommend that prior to collecting recall information about doses taken or missed the prescribed regimen should be reviewed with the patient. Therefore the 7-day adherence recall question will be personalised for each participant, listing their relevant medicines and dosage prescribed based on pharmacy data.

Both adherence questions include a permission statement to normalise non-adherent behaviour and reduce the potential effect of social desirability bias. The final question, from the DAMS, asks participants to select reasons for missing doses of their medication from a list provided. This is intended to allow distinction between intentional and unintentional non-adherence.

8.2.2 PHARMACY REFILL RECORDS

As there is currently no gold standard measure for assessing adherence, it is often recommended that more than one measure be used. The WHO (2003) reported that the current state-of-the-art in measurement of adherence is a multi-method approach combining a self-report measure and another more objective measure. In this study pharmacy refill records will be used to allow for triangulation between measures. This method of measuring adherence focuses on the amount of medication an individual has available rather than the ingestion of medication (Williams et al., 2012). While this approach cannot provide detail on what medications are taken when and how, it can provide an estimate of the highest possible level of medication consumption. Pharmacy refill records are considered a reliable and objective measure of adherence and can be used to corroborate other measures such as self-report without any additional burden on patients (Osterberg and Blaschke, 2005, Bosworth et al., 2006). Pharmacy refill measures have been found to have good predictive validity with HIV viral load and CD4 response, and to correlate well with blood pressure and glycaemic control (Steiner and Prochazka, 1997, Gonzalez and Schneider, 2011, Williams et al., 2012).

8.2.3 CLINICAL INDICATORS OF HEALTH

A systematic review of studies to improve adherence by Haynes et al (2008) advocates the inclusion of clinical outcome measures in a trial of an adherence intervention on the basis of an ethical imperative to have a clinical benefit. A finger prick blood test will be used in this study to test the impact of the intervention on HbA1c levels in patients with Diabetes and cholesterol levels in patients on lipid-lowering drugs. Patients will receive a kit supplied by The Doctor's Laboratory (TDL) London with clear instructions for use. Using this method, participants will use a spring-loaded lancet to draw blood from the finger and fill a collection tube with approximately 20-30 drops of blood. The participant then posts the sample back to the laboratory in a freepost addressed envelope.

8.2.4 HEALTHCARE UTILISATION

Healthcare resource use will be measured in two ways. In the postal questionnaire, patients will be asked to self-report the number of times they have used a range of health services in the previous 3 months. Further data may be sourced using the NHS Information Centre's trusted data linkage service. With patient consent this service can provide data on specific patients' secondary care usage.

8.2.5 BELIEFS ABOUT MEDICINES

Research has suggested that patient's medication adherence is related to their beliefs about their medicines. Influencing beliefs about medicines may, therefore, present an opportunity for improving adherence. In this study participant's beliefs about medicines will be assessed using the Beliefs about Medicines Questionnaire (BMQ) (Horne et al., 1999). The BMQ has shown good validity and reliability in a range of chronic conditions, including asthma, diabetes, psychiatric, renal and cardiovascular disease.

The BMQ has two sections: the BMQ-general covers beliefs about medicines in general, while the BMQ-specific addresses beliefs about particular medicines the patient is taking. This study will use the BMQ-specific scale only. The BMQ-specific comprises two 5-item subscales: a necessity scale that assesses the perceived need for the medication and a concerns scale that gauges the strength of concerns about potential adverse effects of taking medicines. Participants rate each item on a five-point Likert scale from strongly agree to strongly disagree. The difference between the two subscales can be calculated and the resulting 'necessity-concerns differential' has been related to patients' adherence. A high score on the necessity scale and low concerns beliefs have been linked to good adherence (Horne and Weinman, 1999, Phatak and Thomas, 2006, Tibaldi et al., 2009).

8.2.6 MEDICINE-RELATED PROBLEMS

The questionnaire also includes items assessing the problems people experience with their medicines. The items have been developed based on problems related to medicines that have been identified by patients in previous studies in the UK (Barber et al., 2004, Gordon et al., 2007).

8.2.7 DEMOGRAPHICS AND GENERAL HEALTH

Socio-demographic information and a single item assessing general health will be collected to determine whether randomization was successful, to assess their moderating influence on adherence and to determine whether some types of patients are more likely than others to benefit from the intervention.

8.2.8 PATIENTS' SATISFACTION WITH THE INTERVENTION

Participants in the intervention group will receive a supplementary questionnaire at the second and third data collection points. No suitable validated questionnaire was found to assess patient satisfaction with a pharmacist telephone intervention. Some questions were derived from existing scales used in the literature and others were developed to evaluate specific components of this intervention.

8.3 PROCESS MEASURES

A number of process measures will also be extracted from pharmacy records to help assess the fidelity to the intervention protocol and the future practicality of the service. These will include:

- Time and duration of each intervention
- Person providing the intervention
- Number of sessions delivered to each participant
- Number of attempts made to reach participants
- Length of time between each intervention session

9. STATISTICAL CONSIDERATIONS

9.1 SAMPLE SIZE

A sample size calculation was carried out for the primary outcome (self-reported non-adherence) based on the ability to detect a reduction in self-reported non-adherence from 15% to 7.5% in the intervention group compared with the control group at 6 months. This effect size is based on a pharmacy intervention study in a UK population with chronic conditions (Clifford et al., 2006). With 80% power, at a 0.05 significance level (two-sided), and assuming a 10% dropout rate, the sample size required is 612 individuals (306 in the intervention and 306 in the control group).

Based on the data from the pharmacy customer database, this sample size should be feasible within the time frame of the study. Pharmacy records indicate there are approximately 3800 patients on lipid-lowering drugs, and over 1000 patients on drugs for type 2 diabetes.

9.2 STATISTICAL ANALYSIS

Intention to treat analyses will be performed in this study. Multiple imputation method will be used to deal with missing data. Data will be summarized as mean (SD) for continuous variables and number of participants (percent) for categorical variables. Chi-square and analysis of variance tests will be performed to determine significant differences for baseline characteristics between the two groups. A logistic regression model or a mixed regression model will be used to analyze the non-compliance in the intervention and control groups. A number of exploratory analyses will be carried out to assess the differences in health outcomes, healthcare utilization and health related quality of life between the two groups. P values of less than 0.05 will be considered to indicate statistical significance. All statistical analyses will be carried out using SPSS.

REFERENCES

- BARBER, N., PARSONS, J., CLIFFORD, S., DARRACOTT, R. & HORNE, R. 2004. Patients' problems with new medication for chronic conditions. *Quality and Safety in Health Care*, 13, 172-175.
- BOSWORTH, H. B., ODDONE, E. Z. & WEINBERGER, M. (eds.) 2006. *Patient Treatment Adherence: Concepts, Interventions and Measurement*, New Jersey: Lawrence Erlbaum Associates.
- CATZ, S. L., KELLY, J. A., BOGART, L. M., BENOTSCH, E. G. & MCAULIFFE, T. L. 2000. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. *Health Psychology*, 19, 124-133.
- CLIFFORD, S., BARBER, N., ELLIOTT, R., HARTLEY, E. & HORNE, R. 2006. Patient-centred advice is effective in improving adherence to medicines. *Pharmacy World & Science*, 28, 165-170.
- CUTRONA, S. L., CHOUDHRY, N. K., FISCHER, M. A., SERVI, A., LIBERMAN, J. N., BRENNAN, T. & SHRANK, W. H. 2010. Modes of delivery for interventions to improve cardiovascular medication adherence: Review. *American Journal of Managed Care*, 16, 929-942.
- DEPARTMENT OF HEALTH 2008. Pharmacy in England: Building on strengths-delivering the future. London: The Stationary Office.
- DORÓ, P., BENKO, R., CZAKO, A., MATUZ, M., THURZO, F. & SOOS, G. 2011. Optimal recall period in assessing the adherence to antihypertensive therapy: a pilot study. *International Journal of Clinical Pharmacy*, 33, 690-695.
- DUNBAR-JACOB, J., SEREIK, S. M., HOUZE, M., LUYSTER, F. S. & CALLAN, J. A. 2012. Accuracy of Measures of Medication Adherence in a Cholesterol-Lowering Regimen. *Western Journal of Nursing Research*, 34, 578-597.
- FARMER, K. C. 1999. Methods for Measuring and Monitoring Medication Regimen Adherence in Clinical Trials and Clinical Practice. *Clinical Therapeutics*, 21, 1074-1090.
- GAGNÉ, C. & GODIN, G. 2005. Improving self-report measures of non-adherence to HIV medications. *Psychology & Health*, 20, 803-816.
- GARFIELD, S., CLIFFORD, S., ELIASSON, L., BARBER, N. & WILLSON, A. 2011. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. *BMC Medical Research Methodology*, 11, 149.
- GARFIELD, S., ELIASSON, L., CLIFFORD, S., WILLSON, A. & BARBER, N. 2012. Developing the Diagnostic Adherence to Medication Scale (the DAMS) for use in clinical practice. *BMC Health Services Research*, 12, 350.
- GIORDANO, T. P., GUZMAN, D., CLARK, R., CHARLEBOIS, E. D. & BANGSBERG, D. R. 2004. Measuring Adherence to Antiretroviral Therapy in a Diverse Population Using a Visual Analogue Scale. *HIV Clinical Trials*, 5, 74-79.
- GONZALEZ, J. S. & SCHNEIDER, H. E. 2011. Methodological issues in the assessment of diabetes treatment adherence. *Current Diabetes Reports*, 11, 472-479.
- GORDON, K., SMITH, F. & DHILLON, S. 2007. Effective chronic disease management: Patients' perspectives on medication-related problems. *Patient Education and Counseling*, 65, 407-415.
- HAYNES, B. R., MCDONALD HEATHER, P. & GARG, A., X 2002. Helping patients follow prescribed treatment - clinical applications. *JAMA: The Journal of the American Medical Association*, 288, 2880-2883.
- HAYNES, R. B., ACKLOO, E., SAHOTA, N., MCDONALD, H. P. & YAO, X. 2008. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews* [Online]. Available: <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000011/frame.html> [Accessed 4 November 2014].

- HORNE, R. & WEINMAN, J. 1999. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *Journal of Psychosomatic Research*, 47, 555-567.
- HORNE, R., WEINMAN, J. & HANKINS, M. 1999. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*, 14, 1-24.
- JERANT, A., DIMATTEO, R., ARNSTEN, J., MOORE-HILL, M. & FRANKS, P. 2008. Self-Report Adherence Measures in Chronic Illness - Retest Reliability and Predictive Validity. *Medical Care*, 46, 1134-1139.
- KALICHMAN, S. C., AMARAL, C. M., SWETZES, C., JONES, M., MACY, R., KALICHMAN, M. O. & CHERRY, C. 2009. A Simple Single-Item Rating Scale to Measure Medication Adherence: Further Evidence for Convergent Validity. *Journal of the International Association of Physicians in AIDS Care (JIAPAC)*, 8, 367-374.
- KYNGAS, H., DUFFY, M. E. & KROLL, T. 2000. Conceptual analysis of compliance. *Journal of Clinical Nursing*, 9, 5-12.
- LU, M., SAFREN, S., SKOLNIK, P., ROGERS, W., COADY, W., HARDY, H. & WILSON, I. 2008. Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence. *AIDS and behavior*, 12, 86-94.
- MOHER, D., HOPEWELL, S., SCHULZ, K. F., MONTORI, V., GÖTZSCHE, P. C., DEVEREAUX, P. J., ELBOURNE, D., EGGER, M. & ALTMAN, D. G. 2010. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *British Medical Journal*, 340.
- MORISKY, D. E., ANG, A., KROUSEL-WOOD, M. & WARD, H. J. 2008. Predictive Validity of A Medication Adherence Measure in an Outpatient Setting. *Journal of Clinical Hypertension*, 10, 348-354.
- MORISKY, D. E., GREEN, L. W. & LEVINE, D. M. 1986. Concurrent and predictive validity of a self-reported measure of medication adherence. *Medical Care*, 24, 67-74.
- NAU, D. P., STEINKE, D. T., WILLIAMS, L. K., AUSTIN, R., LAFATA, J. E., DIVINE, G. & PLADEVALL, M. 2007. Adherence Analysis Using Visual Analog Scale Versus Claims-Based Estimation. *Annals of Pharmacotherapy*, 41, 1792-1797.
- NUNES, V., NEILSON, J., O'FLYNN, N., CALVERT, N., KUNTZE, S., SMITHSON, H., BENSON, J., BLAIR, J., BOWSER, A., CLYNE, W., CROME, P., HADDAD, P., HEMINGWAY, S., HORNE, R., JOHNSON, S., KELLY, S., PACKHAM, B., PATEL, M. & STEEL, J. 2009. Clinical Guidelines and Evidence Review for Medicines Adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.
- OSTERBERG, L. & BLASCHKE, T. 2005. Adherence to Medication. *New England Journal of Medicine*, 353, 487-497.
- OYUGI, J., BYAKIKA-TUSIIME, J., CHARLEBOIS, E., KITYO, C., MUGERWA, R., MUGYENYI, P. & BANGSBERG, D. 2004. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *Journal of Acquired Immune Deficiency Syndromes*, 36, 1100-1102.
- PEARSON, C. R., SIMONI, J. M., HOFF, P., KURTH, A. E. & MARTIN, D. P. 2007. Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. *AIDS and Behavior*, 11, 161-173.
- PHATAK, H. M. & THOMAS, J. 2006. Relationships Between Beliefs about Medications and Nonadherence to Prescribed Chronic Medications. *Annals of Pharmacotherapy*, 40, 1737-1742.
- SHI, L., LIU, J., FONSECA, V., WALKER, P., KALSEKAR, A. & PAWASKAR, M. 2010. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. *Health and Quality of Life Outcomes*, 8, 99.
- SIMONI, J. M., KURTH, A. E., PEARSON, C. R., PANTALONE, D. W., MERRILL, J. O. & FRICK, P. A. 2006. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. *AIDS and Behavior*, 10, 227-245.

- STEINER, J. F. & PROCHAZKA, A. V. 1997. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. *Journal of Clinical Epidemiology*, 50, 105-116.
- SVARSTAD, B. L., CHEWNING, B. A., SLEATH, B. L. & CLAEISSON, C. 1999. The brief medication questionnaire: A tool for screening patient adherence and barriers to adherence. *Patient Education and Counseling*, 37, 113-124.
- TIBALDI, G., CLATWORTHY, J., TORCHIO, E., ARGENTERO, P., MUNIZZA, C. & HORNE, R. 2009. The utility of the Necessity--Concerns Framework in explaining treatment non-adherence in four chronic illness groups in Italy. *Chronic Illness*, 5, 129-133.
- VAN EIJKEN, M., TSANG, S., WENSING, M., DE SMET, P. A. & GROL, R. P. 2003. Interventions to improve medication compliance in older patients living in the community - A systematic review of the literature. *Drugs & Aging*, 20, 229-240.
- VAN WIJK, B. L., KLUNGEL, O. H., HEERDINK, E. R. & DE BOER, A. 2005. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. *Annals of Pharmacotherapy*, 39, 319-328.
- WAGNER, G. & MILLER, L. G. 2004. Is the influence of social desirability on patients' self-reported adherence overrated? *Journal of Acquired Immune Deficiency Syndromes*, 35, 203-204.
- WALKER, E. A., SHMUKLER, C., ULLMAN, R., BLANCO, E., SCOLLAN-KOLIOPOULUS, M. & COHEN, H. W. 2011. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. *Diabetes care*, 34, 2-7.
- WALSH, J. C., MANDALIA, S. & GAZZARD, B. G. 2002. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. *AIDS*, 16, 269-277.
- WHO 2003. Adherence to Long-term Therapies: Evidence for Action. Geneva: World Health Organisation.
- WILLIAMS, A. B., AMICO, K. R., BOVA, C. & WOMACK, J. A. 2012. A Proposal for Quality Standards for Measuring Medication Adherence in Research. *AIDS and Behavior*, 17, 284-297.

APPENDIX

DATA COLLECTION AND INTERVENTION TIME FRAME

Data Collection	Month	Intervention
	0	Recruitment and consent Letter
Postal questionnaire <i>Demographics</i> <i>General health</i> <i>Beliefs about medicines</i> <i>Medication-related problems</i> <i>Medication adherence</i> <i>Health service utilization</i>		
	1	First telephone consultation Written information by post
	2	Follow-up telephone consultation
Postal questionnaire (4 week follow-up) <i>Beliefs about medicines</i> <i>Medication-related problems</i> <i>Medication adherence</i> <i>Health service utilization</i> <i>Satisfaction with service (intervention group only)</i>	3	
Qualitative telephone interviews ~30 patients	4	
Postal questionnaire (6 month follow-up) <i>Beliefs about medicines</i> <i>Medication-related problem</i> <i>Medication adherence</i> <i>Health service utilization</i> <i>General health</i>	8	
Pharmacy refill adherence	12+	
HES/SUS data <i>Hospitalizations</i>		